Safety of obesity drugs
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The safety of obesity drugs has historically been poor. This and the stigmatisation of obesity in society ensured that a higher standard of safety for obesity drugs must be met. The authors review the safety disasters of obesity drugs that were withdrawn. The authors then review the safety of presently available drugs--benzphetamine, phendimetrazine, diethylpropion, phentermine, sibutramine and orlistat. The safety of rimonabant, a drug with a pending new drug application that has an independent effect on metabolic syndrome, is also reviewed. The authors compare the stage of obesity drug development to that of hypertension in the 1950s. As new and safer drugs with more downstream mechanisms are developed that have independent effects on the cardiovascular risks associated with obesity, third party reimbursement for obesity medicine is likely to improve. This may lead to obesity being treated like hypertension and other chronic diseases with long-term medication. With improved technological tools, the authors believe this process will be more rapid for obesity than it was for hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Haller, C. A., & Benowitz, N. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432502 · Cited by 956
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817
Psychosocial origins of obesity stigma: toward changing a powerful and pervasive bias
Puhl, R. M., & Brownell, K. D. (2003) · Obesity Reviews · doi:10.1046/j.1467-789x.2003.00122.x · Cited by 623
Cannabinoid physiology and pharmacology: 30 years of progress
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608 · cited 1×
“The CB-1 receptor is distributed in the lateral hypothalamus and limbic system, in addition to the gastrointestinal tract and white adipose tissue [106-108].”
BackgroundShekelle, P. G., Hardy, M. L., Morton, S. C., Maglione, M., Mojica, W. A., Suttorp, M. J., Rhodes, S. L., Jungvig, L., & Gagné, J. (2003) · JAMA · doi:10.1001/jama.289.12.1537 · Cited by 511 · cited 1×
“The use of ephedra as an unregulated dietary supplement for the treatment of obesity was accompanied by reports of cardiovascular and neuropsychiatric adverse events, leading to the FDA declaring ephedra an adulterant [83].”
BackgroundMcElroy, S. L., Arnold, L. M., Shapira, N. A., Keck, P. E., Rosenthal, N. R., Karim, M. R., Kamin, M., & Hudson, J. I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.255 · Cited by 484
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476
Padwal, R., Li, S. K., & Lau, D. C. W. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802475 · Cited by 348
Bray, G. A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., & Perry, B. H. (2003) · Obesity Research · doi:10.1038/oby.2003.102 · Cited by 344
Bupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research · doi:10.1038/oby.2002.86 · Cited by 315
Self-citationKelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1033 · Cited by 314
Mitochondrial uncoupling as a target for drug development for the treatment of obesity.
Harper, J. A., Dickinson, K., & Brand, M. D. (2001) · Obesity Reviews · doi:10.1046/j.1467-789x.2001.00043.x · Cited by 250 · cited 1×
“However, there are reports of US clinics on the internet that synthesise dinitrophenol to avoid illegal transportation across state lines for use in the body building community [31].”
BackgroundFujioka, K., Seaton, T. B., Rowe, E., Jelinek, C. A., Raskin, P., Lebovitz, H. E., Weinstein, S. P., & Group, T. S. C. S. (2000) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00081.x · Cited by 244
Allison, D., Zannolli, R., Faith, M., Heo, M., Pietrobelli, A., Vanltallie, T., Pi-Sunyer, F., & Heymsfield, S. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800875 · Cited by 236
for the OBES-002 Study Group, Wilding, J., Gaal, L. V., Rissanen, A., Vercruysse, F., & Fitchet, M. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802783 · Cited by 224
Comparison of continuous and intermittent anorectic therapy in obesity.
Munro, J. F., MacCuish, A. C., Wilson, E. M., & Duncan, L. J. (1968) · BMJ · doi:10.1136/bmj.1.5588.352 · Cited by 215 · cited 2×
“Approximately 50% of those with aminorex-associated primary pulmonary hypertension were dead by 1980, but there was regression of symptoms in ∼ 50% after stopping the drug [59,60].”
BackgroundBupropion SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms
Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., Leadbetter, R. A., Richard, N., Haight, B., Jamerson, B. D., et al. (2002) · Obesity Research · doi:10.1038/oby.2002.142 · Cited by 205
Topiramate: Long‐Term Maintenance of Weight Loss Induced by a Low‐Calorie Diet in Obese Subjects
Astrup, A., Caterson, I., Zelissen, P., Guy‐Grand, B., Carruba, M., Levy, B., Sun, X., Fitchet, M., & OBES‐004 Study Group (2004) · Obesity Research · doi:10.1038/oby.2004.206 · Cited by 143
USE OF DINITROPHENOL IN OBESITY AND RELATED CONDITIONS: A PROGRESS REPORT
TAINTER, M. L., STOCKTON, A. B., & CUTTING, W. C. (1933) · Journal of the American Medical Association · doi:10.1001/jama.1933.02740440032009 · Cited by 112 · cited 2×
“This compound was introduced to treat obesity in 1933 [21,23].”
BackgroundDerosa, G., Cicero, A. F. G., Murdolo, G., Piccinni, M. N., Fogari, E., Bertone, G., Ciccarelli, L., & Fogari, R. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00372.x · Cited by 67 · cited 1×
“A trial comparing orlistat with sibutramine in hypertensive patients over 12 months found that orlistat was associated with a significant decrease in blood pressure whereas the sibutramine group had 2 subjects that required the institution of antihypertensive medication [93].”
BackgroundGullu, S., Altuntas, F., Dincer, I., Erol, C., & Kamel, N. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500655 · Cited by 57 · cited 1×
“This effect may be mediated, at least in part, by the sympathetic nervous system because β-adrenergic blockade improves cardiac function [17].”
Background
Cited by
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association
Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V., Gonzalez-Campoy, J. M., Jones, S. R., Kumar, R., La Forge, R., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.04.001 · Cited by 521
“Historically, weight-management drugs have presented clinical challenges due to issues of safety and tolerability.(252) As a result, from the date of orlistat approval in 1999 through 2012, no new weight-management drugs had”
BackgroundAGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347
Janero, D. R., & Makriyannis, A. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902736568 · Cited by 186
“Consequently, they are recommended only for short-term adjunctive management of exogenous obesity [54] .”
BackgroundVaccination against GIP for the Treatment of Obesity
Fulurija, A., Lutz, T. A., Sladko, K., Osto, M., Wielinga, P. Y., Bachmann, M. F., & Saudan, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003163 · Cited by 136
“unpleasant side-effect profiles [5–7].”
Metadata
- Authors
- Greenway, F. L., & Caruso, M. K.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2005-10-28
- Volume
- 4
- Issue
- 6
- Pages
- 1083-1095
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W1985158305
- Cited by
- 61
- References
- 28
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.